SUPERNOVA: A Strategy of UltraProtective lung ventilation  With Extracorporeal CO2 Removal for New-Onset moderate to seVere ARDS



Study objectives

Extracorporeal CO2(ECCO2R) removal devices (PALP, MAQUET; ILA-active, NOVALUNG; Hemolung, ALung) allowVT and plateau pressure reduction in patients with moderate ARDS. This study aimed to assess changes in pH/ PaO2 /PaCO2, Respiratory Rate and device CO2 clearance in the first 24 hours of ECCO2R following VT and plateau pressure reduction in patients with moderate ARDS. Safety variables during treatment were also analysed.

PILOT trial

Feasibility and safety
100 patients
trial closed


Efficacy and safety of lower versus higher CO2 extraction devices to allow ultraprotective ventilation: secondary analysis of the SUPERNOVA study. Combes A, Tonetti T, Fanelli V, Pham T, Pesenti A, Mancebo J, Brodie D, Ranieri VM.Thorax. 2019 Dec;74(12):1179-1181. doi: 10.1136/thoraxjnl-2019-213591. Epub 2019 Aug 13

Feasibility and safety of extracorporeal CO2 removal to enhance protective ventilation in acute respiratory distress syndrome: the SUPERNOVA study. Combes A, Fanelli V, Pham T, Ranieri VM; European Society of Intensive Care Medicine Trials Group and the “Strategy of Ultra-Protective lung ventilation with Extracorporeal CO2 Removal for New-Onset moderate to severe ARDS” (SUPERNOVA) investigators.Intensive Care Med. 2019 May;45(5):592-600. doi: 10.1007/s00134-019-05567-4. Epub 2019 Feb 21

Research protocol

  • Study design:  to prospectively collect data on 100 patients during usual care in 21 centers.
  • Study devices: PALP, MAQUET; ILA-active, NOVALUNG; Hemolung, ALung. All devices are CE-marked in the European Union.



Supernova steering committee


PRS account number


For more information, please contact